BMO Capital Initiates Coverage On Korro Bio with Outperform Rating, Announces Price Target of $120
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris initiates coverage on Korro Bio (NASDAQ:KRRO) with an Outperform rating and a price target of $120.
February 27, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Korro Bio receives an Outperform rating from BMO Capital with a price target of $120.
The initiation of coverage by BMO Capital with an Outperform rating and a high price target of $120 is a strong positive signal for Korro Bio. This endorsement from a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100